宫颈癌三维近距离治疗中两种常用施源器的剂量学比较

doi:10.3760/cma.j.issn.1004-4221.2017.07.012

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (719 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To compare the dosimetric parameters between the use of Tandem and Ring (TR;Nucletron#090.617) or Tandem and Ovoid (TO;Nucletron#189.730) applicators during three-dimensional (3D) high-dose rate (HDR) brachytherapy (BT) for cervical cancer. Methods The records of 40 cervical cancer (Ⅱ_B-Ⅳ_A) patients treated with 3D-image-guided HDR-BT were reviewed. Of these 40 patients, 20 were treated with the TO applicator, and 20 with the TR applicator. The D_100% and V_150% of the clinical target volume (CTV) and the D_{2 cc} of organs at risk (OAR)(the rectum, bladder, and small intestine) during 3D-HDR-BT using TO and TR were compared using the independent sample t-test. Results
Overall metrics:CTV volume:66.04±13.86 cm³(TR) vs. 65.67±15.08 cm³(TO)(P=0.052);CTV D₁₀₀:3.71±0.34 Gy (TR) vs. 3.37±0.49 Gy (TO)(P=0.016);CTV V_150%:0.54±0.02(TR) vs. 0.56±0.04(TO)(P=0.034);rectum D_{2 cc}:3.38±0.30 Gy (TR) vs. 2.95±0.80 Gy (TO)(P=0.037);bladder D_{2 cc}:4.33±0.39 Gy (TR) vs. 2.93±1.27 Gy (TO)(P=0.00);and small intestine D_{2 cc}:3.04±1.02 Gy (TR) vs. 3.41±0.57 Gy (TO)(P=0.171). Conclusions TR has better CTV coverage than TO during 3D HDR brachytherapy for cervical cancer. In addition, D_{2 cc} of the rectum and bladder were both higher with TR than with TO, though there is no significant dosimetric difference in the small intestine between the two applicators. Therefore, tumor location, extent of invasion, and vaginal conditions should be considered when selecting the suitable applicator for the treatment of cervical cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Feng Xi
	Wang Xianliang
	Yuan Ke
	Tan Yankee
	Zhang Dekang

Key words： Applicators Cervical neoplasms/brachytherapy Dosimetry

Received: 11 May 2016

Corresponding Authors: Zhang Dekang:Email:1796280224@qq.com

Cite this article:

Feng Xi,Wang Xianliang,Yuan Ke et al. Dosimetric comparison between two brachytherapy applicators in cervical cancer treatment[J]. Chinese Journal of Radiation Oncology, 2017, 26(7): 778-780.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.07.012 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I7/778

[1] Haie-Meder C,P tter R,Van Limbergen E,et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I):concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J].Radiother Oncol,2005,74(3):235-245.DOI:10.1016/j.radonc.2004.12.015.
[2] Viswanathan AN,Thomadsen B.American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part I:general principles[J].Brachytherapy,2012,11(1):33-46.DOI:10.1016/j.brachy.2011.07.003.
[3] Haack S,Nielsen SK,Lindegaard JC,et al. Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer[J].Radiother Oncol,2009,91(2):187-193,DOI:10.1016/j.radonc.2008.09.002.
[4] Kirisits C,P tter R,Lang S,et al. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer[J].Int J Radiat Oncol Biol Phys,2005,62(3):901-911.DOI:10.1016/j.ijrobp.2005.02.040.
[5] Berger D,Dimopoulos J,Georg P,et al. Uncertainties in assesment of the vaginal dose for intracavitary brachytherapy of cervical cancer using a tandem-ring applicator[J].Int J Radiat Oncol Biol Phys,2007,67(5):1451-1459.DOI:10.1016/j.ijrobp.2006.11.021,
[6] Kuo L,Viswanathan A,Damato A,et al,SU-E-T-310:dosimetric comparison of tandem and ovoid (TO) vs.tandem and ring (TR) applicators in high-dose rate (HDR) brachytherapy (BT) for the treatment of locally-advanced cervical-cancer[J].Med Phys,2015,42(6):3404.DOI:10.1118/1.4924671.
[7] 赵红福.韩冬梅.程光惠.等.宫颈癌三维适形近距离治疗腔内联合插植施源器对比研究[J].中华放射肿瘤学杂志,2016,25(4):362-366.DOI:10.3760/cma.j.issn.1004-4221.2016.04.012.
Zhao HF,Han DM,Cheng GH,et al. A comparative study of Utrecht interstitial applicator and ring interstitial applicator in three-dimensional conformal brachytherapy for cervical cancer[J].Chin J Radiat Oncol,2016,25(4):362-366.DOI:10.3760/cma.j.issn.1004-4221.2016.04.012.
[8] A European study on MRI-guided brachytherapy in locally advanced cervical cancer[EB/OL][2016-05-09].https://www.embracestudy.dk/.
[9] Hellebust TP,Kirisits C,Berger D,et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group:considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy[J].Radiother Oncol,2010,96(2):153-160.DOI:10.1016/j.radonc.2010.06.004.
[10] Saha S,Gangopadhyay A,Ghoshdastidar A,et al. Image-guided HDR intracavitary and interstitial brachytherapy for locally advanced cervix cancer-correlation of late toxicity with DVH data and 3-year outcome analysis[J].Brachytherapy,2008,7:98.DOI:10.1016/j.brachy.2008.02.353.
[11] Vinod SK,Caldwell K,Lau A,et al. A comparison of ICRU point doses and volumetric doses of organs at risk (OARs) in brachytherapy for cervical cancer[J].J Med Imaging Radiat Oncol,2011,55(3):304-310.DOI:10.1111/j.1754-9485.2011.02272.x.
[12] Hellebust TP,Tanderup K,Lerv g C,et al. Dosimetric impact of interobserver variability in MRI-based delineation for cervical cancer brachytherapy[J].Radiother Oncol,2013,107(1):13-19.DOI:10.1016/j.radonc.2012.12.017.
[13] 晏俊芳,于浪,孙玉亮,等.以CT图像为基础的宫颈癌三维腔内放疗[J].中华放射肿瘤学杂志,2014,23(5):377-381.DOI:10.3760/cma.j.issn.1004-4221.2014.05.002.
Yan JF,Yu L,Sun YL,et al. A clinical study of CT image-based 3D brachytherapy for cervical cancer[J].Chin J Radiat Oncol,2014,23(5):377-381.DOI:10.3760/cma.j.issn.1004-4221.2014.05.002.